17 September 2018

LGB Corporate Finance appoints Andrew Hay as Chairman

LGB Corporate Finance is delighted to announce the appointment of Andrew Hay as Chairman. A senior corporate financier with significant experience and extensive connections, Andrew has joined the team in response to growing demand for its M&A advisory and debt and equity financing services. His appointment will enable LGB Corporate Finance to increase the depth and breadth of service to its clients.

Andrew has worked in senior corporate finance roles at Schroders, ING Barings and latterly Edmond de Rothschild in London, where he led the corporate finance team for over ten years. Andrew has advised UK and international companies, listed and privately owned, on a wide range of M&A and financing transactions.

Angus Grierson, Managing Director of LGB Corporate Finance, commented:  “We are delighted that Andrew has joined LGB Corporate Finance as Chairman. We look forward to leveraging Andrew’s connections and his in-depth transaction experience, drawing on his expert knowledge to enhance our financing and M&A advisory services to public companies, owner-managed businesses and financial sponsors.”

Andrew Hay, Chairman of LGB Corporate Finance, commented: “I am very pleased indeed to be joining LGB Corporate Finance. The business was formed in 2005 and I have been very impressed by the firm’s reputation, the scope of its advisory business – acting across the capital structure – and the skills the team consistently bring to bear on behalf of clients. They demonstrate clearly that a focused advisory business with excellent people, in charge of its own destiny, is a very effective partner for growth companies. I very much look forward to working with them.”

Recent Articles

14 June 2019

Canadian IT services company CGI is acquiring SCISYS Group plc

SCISYS Group plc has received a cash offer from Canadian company CGI Inc. The offer price of 254.15p represents a 24.6% premium to yesterday’s closing price and values SCISYS at c£78.9m. Read more

Deals

13 June 2019

Scancell issues new shares to Vulpes Life Sciences Fund

Scancell (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer, has raised £3.89m by the issue of new ordinary shares to Vulpes Life Sciences Fund.

Read more

Deals

29 April 2019

AIM for growth businesses looking to scale up is still an option

Ivan Sedgwick, Investments Director at LGB & Co. Limited, wrote an article for Growth Business on why AIM needs to attract institutional interest and improve transparency and governance.

 

Read more

News & Insights